M. Scott Lucia, MD

M. Scott Lucia, MD

University of Colorado, Denver

Aurora, Colorado

M. Scott Lucia, MD, is Professor and Vice Chair of Anatomic Pathology and Chief of Genitourinary and Renal Pathology at the University of Colorado School of Medicine, where he also serves as the Director of the UCAMC Biorepository Core Facility. Dr. Lucia currently serves as the Pathology Chair for the Genitourinary Subcommittee of the Southwest Oncology Group (SWOG). He has served as the Central Pathologist for a number of SWOG clinical trials in prostate and bladder cancer, including the Prostate Cancer Prevention Trial (PCPT) and Vitamin E and Selenium Chemoprevention Trial (SELECT). He also served as the Principal Pathologist for the Medical Therapy of Prostate Symptoms (MTOPS) trial, sponsored by the NIDDK, and the Reduction with Dutasteride of Clinical Progression Events in Expectant Management of Prostate Cancer (REDEEM), sponsored by GlaxoSmithKline. He directs the operation of several tissue and serum biorepositories for prostate and prostatic diseases, including those for the PCPT, MTOPS, SELECT, and the University of Colorado Cancer Center Prostate Biorepository. He has authored or co-authored over 190 peer-reviewed articles, reviews, editorials, and book chapters. His primary areas of interest include pathology of prostate cancer and hyperplasia, early detection and prevention of prostate cancer, prostate cancer biomarkers, and prostatic inflammation.

Articles by M. Scott Lucia, MD

FDUS 2018 – Next Generation in Biomarkers

M. Scott Lucia, MD, led the “Next Generation in Biomarkers” session at the Future Directions in Urology Symposium (FDUS) 2018. These consensus statements represent a comprehensive analysis of current issues, challenges, and advancements in urology from a panel of international experts.

Read More

Changing Distribution, Size and Grade of Prostate Cancer: Whole-Mount Prostatectomy Analysis

M. Scott Lucia, MD, summarizes the changes in the clinical management of prostate cancer since 1990, specifically regarding PSA screening, active surveillance, targeted focal therapy, and pathology grading practices. Also, he analyzes whole-mount prostatectomy data from the past 16 years that has shown increasingly higher grade and volume tumors. He then discusses whether or not this is exclusively due to patient selection and over-grading.

Read More

Join the GRU Community

- Why Join? -